TheCOVIDBlog.com - June 13, 2021
SESTRI LEVANTE, LIGURIA — An 18-year-old woman is dead, prompting many young people in her area to cancel their previous plans for injections.
Ms. Camilla Canepa received the first dose of experimental AstraZeneca viral vector DNA on May 25, according to several Italian media sources. It was an “open day” for anyone over the age of 18 to receive experimental injections, particularly AstraZeneca.
She checked into the emergency room at Lavagna Hospital on June 3, complaining of severe headaches and extreme light sensitivity. A CT scan and neurological tests found nothing, so doctors discharged her with an order to return in 15 days for further tests. But Ms. Canepa returned to the ER at San Martino Hospital in Genoa just two days later. She now suffered from paralysis in at least one part of her body.
Ms. Canepa was diagnosed with cavernous sinus thrombosis, meaning a blood clot in the space between the eye sockets and brain. It blocked the primary vein between the head and heart. Doctors also discovered that she was bleeding inside her brain. Ms. Canepa underwent two surgeries, one to remove the blood clot and the second to relieve pressure in her head caused by the bleeding. But the damage was too great to overcome.
Ms. Canepa passed away on June 10.
----------------
«Autoimmune thrombocytopenia is a much less serious disease than Vitt (vaccine-induced immune thrombotic thrombocytopenia) and has negligible mortality in young people. It also does not represent a known risk factor for rare thrombosis associated with viral vector vaccines. ‘ The hematologist Pier Mannuccio Mannucci, Emeritus Professor of Internal Medicine at the University of Milan and member of the Aifa (Italian Medicines Agency) commission for the evaluation of the thrombosis risk associated with the anti Covid vaccination, comments on the news relating to Camilla Canepa, the 18-year-old who died on 10 June at the San Martino hospital in Genoa due to a very serious cerebral thrombosis and consequent haemorrhage. On May 25, Camilla was vaccinated in Genoa, taking advantage of an “open day”, and had received the first dose of AstraZeneca.
Professor, why is autoimmune thrombocytopenia (Itp) different from “vaccine-induced immune thrombotic thrombocytopenia”?
“Autoimmune thrombocytopenia is generally not accompanied by thrombotic events and the antibodies that are formed are directed against the surface proteins of platelets. The latter, damaged, are eliminated by the spleen. This leads to platelet deficiency. The precise mechanism that triggers Vitt is not yet known, but it certainly includes a process of autoimmunity, ie the production of autoantibodies against the fourth platelet factor and the creation of a “polyanion”. Factor 4 is a positively charged substance, ie a cation, and there is a negatively charged substance, an anion, which binds to platelet factor 4; then autoantibodies are produced which bind to platelets, activate them and trigger hypercoagulability. At the same time the autoantibodies cause the platelets to be consumed, hence thrombocytopenia. This is a well known process, what is not yet clear is what is this polyanion which looks like heparin but is not heparin. It is a negatively charged substance that, according to some hypotheses, could be produced with viral vector vaccines. The mechanism of Itp and Vitt is similar, but the antibodies and antigens are different ».
--------------------
0 Comments